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Abstract
Background: Current guidelines from the European Society of Cardiology (ESC) define low thresholds for the
diagnosis of dyslipidemia using total cholesterol (TC) and LDL-cholesterol (LDL-C) to guide treatment. Although
being mainly a prevention tool, its thresholds are difficult to meet in clinical practice, especially primary care.
Methods: In a nationwide study with 1,511 primary care physicians and 35,869 patients we determined the
prevalence of dyslipidemia, its recognition, treatment, and control rates. Diagnosis of dyslipidemia was based on
TC and LDL-C. Basic descriptive statistics and prevalence rate ratios, as well as 95% confidence intervals were
calculated.
Results: Dyslipidemia was highly frequent in primary care (76% overall). 48.6% of male and 39.9% of female
patients with dyslipidemia was diagnosed by the physicians. Life style intervention did however control
dyslipidemia in about 10% of patients only. A higher proportion (34.1% of male and 26.7% female) was controlled
when receiving pharmacotherapy. The chance to be diagnosed and subsequently controlled using
pharmacotherapy was higher in male (PRR 1.15; 95%CI 1.12–1.17), in patients with concomitant cardiovascular
risk factors, in patients with hypertension (PRR 1.20; 95%CI 1.05–1.37) and cardiovascular disease (PRR 1.46;
95%CI 1.29–1.64), previous myocardial infarction (PRR 1.32; 95%CI 1.19–1.47), and if patients knew to be
hypertensive (PRR 1.18; 95%CI 1.04–1.34) or knew about their prior myocardial infarction (PRR 1.17; 95%CI
1.23–1.53).
Conclusion: Thresholds of the ESC seem to be difficult to meet. A simple call for more aggressive treatment or
higher patient compliance is apparently not enough to enhance the proportion of controlled patients. A shift
towards a multifactorial treatment considering lifestyle interventions and pharmacotherapy to reduce weight and
lipids may be the only way in a population where just to be normal is certainly not ideal.
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Background
Dyslipidemia is one of the top 5 major risk factors leading
to cardiovascular disease. Its treatment has been shown to
improve prognosis – morbidity and mortality is substan-
tially reduced in successfully treated as compared to non-
treated dyslipidemic controls [1-3].
Although there are differences in defining dyslipidemia
and the goals to achieve when treating dyslipidemia there
is a general trend to recommend low treatment targets for
total cholesterol (TC) and LDL-cholesterol (LDL-C) in all
major guidelines (Table 1).
The European guideline on cardiovascular disease preven-
tion in clinical practice for example recommends a TC of
below 190 mg/dl (5.0 mmol/l) and an LDL-C of below
115 mg/dl (3.0 mmol/l) for the general population.
When additional comorbidity is present (coronary artery
disease (CAD), other cardiovascular disease (CVD) or dia-
betes mellitus) the goals are even lower: < 175 mg/dl (4.5
mmol/l) for TC and < 100 mg/dl (2.6 mmol/l) for LDL-C
[4].
The National Cholesterol Education Program (NCEP)
guidelines chose another approach to define LDL-C tar-
gets based on the presence of additional risk factors: For
patients with maximum 1 risk factor LDL-C levels of < 160
mg/dl (4.1 mmol/l) are targeted. Patients with 2 or more
risk factors or a 10-year risk for CAD (myocardial infarc-
tion or CAD death) of less than 20% LDL-C levels < 130
mg/dl (3.4 mmol/l) are targeted. If patients already show
CAD or CAD risk equivalent (other clinical forms of
atherosclerotic disease, diabetes mellitus, or a 10 year-risk
for CAD greater than 20%) an LDL-C goal of < 100 mg/dl
(2.6 mmol/l) is recommended [5] which is identical to
the European guideline [4]. The NCEP coordination com-
mittee, encouraged by the results of major statin trials,
even recommended a goal for LDL-C of less than 70 mg/
dl (1.8 mmol/l) in patients at very high risk, at least as a
therapeutic option [6].
Available treatments include life-style interventions and
pharmacotherapy and these treatments have been shown
to successfully alleviate the extent of dyslipidemia if
applied rigorously. Statins are highly effective and are pre-
scribed to > 85% of medically treated dyslipidemic
patients in primary care in Germany [7,8] either alone
(92.9%) or in combination with ezetimibe (3.1%) or
fibrates (1.5%). But still there is a substantial gap between
the number of patients at risk and the number of patients
(successfully) treated to target [7,8] calling for a more in
depth understanding of the treatment strategies and path-
ways, the specific patient type commonly difficult to con-
trol and the barriers to overcome in primary care[9]. This
could also lead to an improvement in the design of clini-
cal studies to be applicable to a broader population and in
particular to the situation in primary care where multiple
partly unrelated morbidities meet and treatment is always
a trade off between what the guidelines tell and what prac-
tice (and budget) allows.
Therefore the dataset of a recent nationwide study with
1,511 physicians (GErman Metabolic and Cardiovascular
riSk Project, GEMCAS) documenting 35,869 patients in
primary care was used to describe – from a physician per-
spective -current treatment of dyslipidemia. The following
questions were investigated: 1) what is the prevalence of
dyslipidemia (treated and untreated) in primary care, 2)
what factors are associated with not being recognized,
being treated (with or without pharmacotherapy), and
finally being controlled if dyslipidemia is known, 3) are
there differences with respect to patients in primary pre-
vention compared to high risk patients (high risk patients
or pre-existing cardiovascular disease).
Table 1: treatment targets for total cholesterol (TC) and LDL-cholesterol (LDL-C) in the ESC and NCEP guidelines
Total cholesterol (TC) Low density cholesterol (LDL-C)
mg/dl mmol/l mg/dl mmol/l
ESC guideline [4]
General population 190 5.0 115 3.0
CAD, CVD or DM 175 4.5 100 2.6
NCEP guideline [6,5]
0 or 1 RF 160 4.1
> 2 RF or 130 3.4
CAD event risk < 20%
CAD or risk equivalent* 100 2.6
optional in very high risk 70 1.8
ESC, European Society of Cardiology; CAD, coronary artery disease; CVD, cardiovascular disease; DM, diabetes mellitus; NCEP, National 
Cholesterol Education Program; *other clinical forms of atherosclerotic disease, diabetes mellitus, or a 10 year-risk for CAD greater than 20%.Cardiovascular Diabetology 2008, 7:31 http://www.cardiab.com/content/7/1/31
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Methods
Study design and participating physicians
We analysed the dataset of a nationwide cross-sectional
prevalence study in primary care. General practitioners
and internists with focus on primary health care (GPs)
were selected by a stratified, randomized sampling
method to receive a random distribution across all Ger-
man regions. The methods of this study have been
described in detail earlier [10].
Study population
The study population comprised all male and female
patients ≥ 18 years of age who visited their GP at the par-
ticipating sites on the day of the survey regardless of the
reason for visiting and who gave their written informed
consent to participate. The only reasons for exclusion were
conditions that made it impossible for the patient to par-
ticipate (serious disabilities or diseases, acute emergen-
cies, or pregnancies and breast-feeding within the
previous 3 months). The study protocol did not allow for
further selection of patients. All patients who were eligible
on the given day were included consecutively. In total,
1,511 general practices from 397 out of 438 German cities
and administrative districts enrolled 35,869 patients (age
range: 18 – 99, women 61.1%).
Laboratory analysis
An initial screening blood glucose quick test from a capil-
lary (finger stick) was performed in every patient and the
results were documented in the reporting form. Addition-
ally, for each patient, venous blood samples were col-
lected and shipped within 24 hours to the central
laboratory (Labor 28, Berlin, Germany) by an assigned
courier service. The blood samples were analyzed for lev-
els of glucose, LDL-cholesterol, HDL-cholesterol, total
cholesterol and triglycerides. GPs were equipped from the
central laboratory with pre-labelled serum- and natrium-
fluoride-(NaF) tubes for taking the samples.
Diagnostic conventions
Dyslipidemia was defined on the basis of the European
guidelines on cardiovascular disease prevention in clinical
practice [4] using TC and LDL-C to guide treatment. In
general TC < 190 mg/dl and LDL-C < 115 mg/dl were
regarded as normal (non dyslipidemic). In patients with
established cardiovascular disease (items: myocardial inf-
arction/acute coronary syndrome, stroke/TIA, PAD if
questionnaire indicated to be present) or type-2-diabetes
mellitus thresholds of < 175 for TC and < 100 mg/dl for
LDL-C were applied. So if patients exceeded either one of
their thresholds, dyslipidemia was assumed. HDL-C and
triglycerides were not used to define dyslipidemia. Ongo-
ing treatment or doctors' diagnosis (lipid disorder indi-
cated to be present) was likewise defined as dyslipidemia.
Lipid lowering agents were assumed to be necessary in
dyslipidemic patients if the absolute risk based on the
SCORE Scoring system exceeded 5% [11] or 20% on the
PROCAM Score [12].
Statistical analyses
For the main variables of the study, basic descriptive sta-
tistics (number of observations, mean, median, propor-
tions) and corresponding measures of variability
(standard deviation, standard error of the mean, 95%
confidence intervals) were calculated. Crude and adjusted
prevalence rate ratios PRRs and 95% confidence intervals
were computed with the SAS procedure GENMOD. All
statistical analyses were conducted using the statistical
software package SAS 9.1 (SAS Institute, Cary, NC, USA)
[13].
Results
Sample characteristics
Basis of the present analysis was a sample of 35,869
patients from the GEMCAS study. Patients had a mean age
of 51.7 ± 16.1 years and a mean BMI of 26.9 ± 5.2 kg/m2.
Patients with dyslipidemia were more frequently male,
past smokers, had a higher BMI and waist circumference,
and had more frequently cardiovascular disease (Table 2).
Overall 76.4% of patients in GEMCAS met the criteria of
the ESC for the diagnosis of dyslipidemia [4].
Prevalence of dyslipidemia by age group and gender
Dyslipidemia, based on the current ESC guideline defini-
tion, was a frequent condition in all age groups from 18
up to 100 years (Figure 1). While the proportion of dysli-
pidemic patients was low in the young age group (20.9%
in male and 39.8% in female patients up to an age of 20
years) it peaked in the age group of 61 – 70 years in both
genders with a gradual decline thereafter, more so in male
than in female patients.
Characteristics of patients with diagnosed dyslipidemia
The proportion of patients whose dyslipidemia was
known to the treating physician was between 9.5 and
64.3% in men, and 5.7 and 63.6% in women. Highest
rates were seen in men between 61 and 70 years, the low-
est in female patients between 18 and 20 years (Figure 2).
Table 3 displays that the proportion of diagnosed patients
was generally higher in women than in men (PRR 1.15
[95%CI 1.12–1.17]), likewise this was true for higher age
(PRR 1.68 [95%CI 1.64–1.72]), risk factors like type-2-
diabetes (PRR 1.51 [95%CI 1.41–1.58]), hypertension
(PRR 1.70 [95%CI 1.65–1.76]), and a high BMI (PRR 1.48
[95%CI 1.42–1.53]) and WC (PRR 1.50 [95%CI 1.44–
1.56]). Patients with cardiovascular end organ damage
(cardiovascular disease, PAD, stroke, myocardial infarc-
tion, and heart failure) had more often a diagnosis of dys-
lipidemia. The same was true for patients with liver
disease (PRR 1.57 [95%CI 1.47–1.68]).Cardiovascular Diabetology 2008, 7:31 http://www.cardiab.com/content/7/1/31
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Patients' knowledge about cardiovascular risk factors and
disease was also associated with a higher proportion of a
diagnosis of dyslipidemia (Hypertension, MI, Diabetes,
and many dietary attempts).
Controlled dyslipidemia in patients with life style 
intervention or no therapy
The overall percentage that dyslipidemia in patients with
no pharmacotherapy but life style intervention or no ther-
apy at all is controlled was low (about 10%). The percent-
age of controlled dyslipidemia increased when patients
were male (PRR 2.00; [95%CI 1.60–2.50]), had type-2-
diabetes (PRR 1.37 [95%CI 1.10–1.72]), prior MI (PRR
1.48; [95%CI 1.09–2.01]), CVD (PRR 1.34 [95%CI 1.06–
1.70]), or heart failure (PRR 1.78 [95%CI 1.32–2.40]). If
patients knew about their MI (PRR 2.13 [95%CI 1.53–
2.96]), had diabetes (PRR 1.38 [95%CI 1.10–1.74]), or
reported dyspnoea on exertion (PRR 1.82 [95%CI 1.05–
3.17]) control of dyslipidemia was increased (Table 3).
Controlled dyslipidemia in patients on pharmacotherapy
Up to 62.4% of male and 48.7% of female patients with
known dyslipidemia were treated with pharmacotherapy
(Figure 2). There was an age-related increase in both gen-
Table 2: Baseline characteristics of the GEMCAS sample according to the presence or absence of dyslipidemia
Total sample4 No dyslipidemia Dyslipidemia
N % N % 95%CI N % 95%CI
Gender 35 551 8 393 27 158
female 21 711 61.1 5 421 64.6 63.6–65.6 16 290 60.0 59.4–60.6
male 13 840 38.9 2 972 35.4 34.4–36.4 10 868 40.0 39.4–40.6
Smoker 34 508 8 184 26 324
present 8 629 25.0 2 536 31.0 30.0–32.0 6 093 23.1 22.6–23.7
past 10 058 29.1 2 016 24.6 23.7–25.6 8 042 30.6 30.0–31.1
BMI 35 469 8 374 27 095
overweight (BMI 25–29.9) 12 941 36.5 2 233 26.7 25.7–27.6 10 708 39.5 38.9–40.1
obese (BMI 30-) 8 468 23.9 1 289 15.4 14.6–16.2 7 179 26.5 26.0–27.0
Waist circumference 35 360 8 344 27 016
normal1 13 327 37.7 4 758 57.0 56.0–58.1 8 569 31.7 31.2–32.3
elevated2 8 058 22.8 1 483 17.8 17.0–18.6 6 575 24.3 23.8–24.9
high3 13 975 39.5 2 103 25.2 24.3–26.1 11 872 43.9 43.4–44.5
Cardiovascular Disease5
overall CVD 5 509 15.5 658 7.8 7.3–8.4 4 851 17.9 17.4–18.3
MI/ACS 2 234 6.6 208 2.6 2.2–3.0 2 026 7.8 7.5–8.1
Stroke/TIA 905 2.7 116 1.4 1.2–1.7 789 3.1 2.9–3.3
PAD 839 2.5 82 1.0 0.8–1.3 757 3.0 2.7–3.2
Heart Failure 1 959 5.7 236 2.9 2.5–3.3 1 723 6.6 6.3–6.9
Diabetes
Type 1 (acc. to GP) 199 0.6 45 0.6 0.4–0.8 154 0.6 0.5–0.7
Type 2 (acc. to GP) 4 274 12.6 492 6.2 5.6–6.7 3782 14.6 14.2–15.1
mean ± SD mean 95%CI mean 95%CI
Age 51.7 ± 16.1 42.2 42.6–41.9 54.7 54.5–54.9
BMI 26.9 ± 5.2 25.2 25.1–25.3 27.5 27.4–27.6
Blood Pressure
systolic 130.5 ± 19.1 123.7 123.4–124.1 132.6 132.4–132.8
diastolic 80.0 ± 10.6 77.2 77.0–77.4 80.9 80.8–81.0
Lipids (mg/dL)
total Cholesterol 206.8 ± 41.5 162.7 162.3–163.1 220.2 219.8–220.7
HDL-Cholesterol 62.2 ± 17.3 61.3 61.0–61.6 62.5 62.3–62.7
LDL-Cholesterol 128.0 ± 36.6 90.0 89.7–90.4 139.6 139.2–140.0
Triglycerides 152.4 ± 123.5 110.0 108.5–111.5 165.2 163.6–166.8
Blood sugar (mg/dL)
random glucose 98.0 ± 32.2 91.6 91.0–92.1 99.9 99.5–100.3
fasting glucose 96.1 ± 25.5 90.3 89.6–91.1 97.5 97.1–98.0
1 normal WC: male ≤ 94, female ≤ 80 cm; 2 elevated WC: male > 94 & ≤ 102 cm, female > 80 & ≤ 88 cm; 3 high WC: male > 102 cm, female > 88 
cm; 4 N = 35869 total patients in study; 5 overall CVD according to GP and/or patient. Spec. CVD according to GPCardiovascular Diabetology 2008, 7:31 http://www.cardiab.com/content/7/1/31
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Proportion of patients in different age groups being dyslipidemic as the the 2003 ESC guidelines Figure 1
Proportion of patients in different age groups being dyslipidemic as the the 2003 ESC guidelines. Total dyslipi-
demia is defined as either "lipid disorders yes" or "lipid lowering agent yes" or lab values compatible with the diagnosis of dysl-
ipidemia as previously defined. Reference for each percent number given is the total number of patients in that age group 
indicted in the upper part of the figure.
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Table 3: Comparison of patients with a) known vs. unknown dyslipidemia; b) controlled without pharmacotherapy (drugs) vs. uncontrolled and c) controlled with 
pharmacotherapy (drugs) vs. uncontrolled
Known vs. unknown dyslipidemia Controlled without drugs vs. uncontrolled Controlled with drugs vs. uncontrolled
N PRR 95%CI N PRR 95%CI N PRR 95%CI
Male gender vs. female 5 296 1.151 1.12;1.17 181 2.001 1.60;2.50 663 1.301 1.67;1.44
Age > 65 years vs. ≤ 65 4 485 1.682 1.64;1.72 110 0.972 0.78;1.22 569 1.142 1.03;1.26
Risk factors
Type-2-Diabetes vs. none 2 840 1.51 1.44;1.58 137 1.37 1.10;1.72 463 0.95 0.86;1.05
Hypertension (140/90) vs. no 3 995 1.70 1.65;1.76 104 1.06 0.83;1.35 337 1.20 1.05;1.37
BMI ≥ 30 vs. < 25 kg/m2 3 999 1.48 1.42;1.53 134 1.15 0.87;1.54 361 0.84 0.73;0.97
WC > 102/88 cm vs. normal 6 400 1.50 1.44;1.56 187 0.99 0.76;1.30 588 0.77 0.68;0.87
Co-morbid disease
CVD vs. no 3 609 1.45 1.41;1.50 121 1.34 1.06;1.70 770 1.46 1.29;1.64
MI vs. no 1 695 1.24 1.20;1.29 46 1.48 1.09;2.01 494 1.32 1.19;1.47
Stroke vs. no 607 1.26 1.16;1.37 18 1.08 0.69;1.71 139 1.08 0.93;1.25
PAD vs. no 621 1.33 1.22;1.44 21 1.17 0.76;1.79 147 1.07 0.93;1.24
Heart Failure vs. no 1 284 1.05 1.02;1.08 52 1.78 1.32;2.40 241 1.11 0.98;1.25
Liver disease vs. no 1 436 1.57 1.47;1.68 56 1.29 0.95;1.75 144 0.94 0.79;1.11
Patient self reported
School < 10 years vs. ≥ 10 6 751 1.14 1.11;1.18 181 1.17 0.92;1.48 633 0.89 0.80;0.99
Apprenticeship vs. > Appr. 9 138 1.06 1.02;1.11 244 1.62 1.07;2.47 789 0.80 0.70;0.91
Hypertension vs. no 6 668 1.56 1.51;1.61 180 1.17 0.92;1.49 768 1.18 1.04;1.34
MI vs. no 1 061 1.51 1.41;1.61 36 2.13 1.53;2.96 324 1.37 1.23;1.53
Stroke vs. no 601 1.24 1.14;1.35 17 1.14 0.71;1.82 129 1.07 0.92;1.25
Diabetes vs. no 2 590 1.51 1.45;1.58 119 1.38 1.10;1.74 430 1.01 0.91;1.12
Dyslipidemia vs. no 7 928 3.80 3.64;3.96 145 0.59 0.46;0.75 741 0.70 0.61;0.79
Liver vs. no 933 1.18 1.14;1.21 29 1.10 0.77;1.59 86 1.01 0.84;1.21
Kidney vs. no 968 1.01 0.98;1.03 26 1.14 0.77;1.67 103 1.01 0.86;1.20
Rheuma vs. no 1 235 1.04 1.02;1.06 30 1.15 0.80;1.66 103 0.91 0.76;1.08
Cancer vs. no 917 0.98 0.94;1.02 26 1.23 0.83;1.81 86 1.01 0.84;1.21
Arthrosis vs. no 4 543 1.10 1.07;1.13 97 0.95 0.74;1.22 398 0.87 0.77;0.97
Sports > 4 h vs. ≤ 4 h 941 1.06 1.01;1.12 22 1.05 0.70;1.59 98 0.87 0.74;1.03
Dyspnea on stairs vs. none 5 413 1.12 1.07.1.16 144 1.82 1.05;3.17 544 0.83 0.63;1.10
Smoking ever vs. never 6 222 1.06 1.04;1.09 178 1.16 0.91;1.48 585 0.87 0.78;0.97
Diet many vs. none 343 1.50 1.35;1.68 10 1.39 0.75;2.60 24 0.90 0.64;1.29
PRR, prevalence rate ratios adjusted for age and gender; 1 only age adjusted, 2only sex adjustedCardiovascular Diabetology 2008, 7:31 http://www.cardiab.com/content/7/1/31
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Known, treated and controlled dyslipidemia in primary care Figure 2
Known, treated and controlled dyslipidemia in primary care. Known dyslipidemia is defined as either "lipid disorders 
yes" or "lipid lowering agent yes". Treated dyslipidemia is defined as "lipid lowering agent yes". Controlled dyslipidemia is 
defined as "lipid lowering agent yes" and lab values within the limits previously defined. Reference for each percent number 
given is the number of patients in the previous category, e.g. 11.9% of the 20.9% dyslipidemic patients in the age group 18–20 
are known to be dyslipidemic by their treating physician.
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ders until the age group 81 – 90 in men and until the age
group 71 – 80 in women. Control rates on pharmacother-
apy varied between 28.4 and 100.0% in men and 24.4 –
100.0% in women.
Patients with higher age (> 65 years, PRR 1.14 [95%CI
1.03–1.26]), with hypertension (PRR 1.20 [95%CI 1.05–
1.37]), cardiovascular disease like CVD (PRR 1.46 [95%CI
1.29–1.64]), and MI (PRR 1.32 [95%CI 1.19–1.47]) were
more likely to be controlled using pharmacotherapy.
Patients with a high BMI (PRR 0.84 [95%CI 0.73–0.97])
or WC (PRR 0.77 [95%CI 0.68–0.87]) were less likely well
controlled (Table 3). Additionally, patients reporting a
low level of education (< 10 years of schooling, PRR 0.89)
and apprenticeship only (PRR 0.80) as well as patients
reporting to have arthritis (PRR 0.87) or having ever
smoked (PRR 0.87) had lowest rates of control.
Control rates in high risk patients with and without 
existing CVD
It is recommended by international guidelines that
patients without existing cardiovascular disease (primary
prevention) should receive lipid lowering therapy if their
SCORE score exceeds 5% or their PROCAM score 20% or
when Diabetes mellitus is present [14]. These patients are
the basis of Figure 3. Amongst these about 2/3 were
known to have dyslipidemia, 1/3 was treated with phar-
macotherapy (with an age-dependent increase from 22.2
to 47.7%) and little more than 10% were finally control-
Dyslipidemia treatment and control in patients with a SCORE Score > 5%, PROCAM Score > 20% or Diabetes mellitus Figure 3
Dyslipidemia treatment and control in patients with a SCORE Score > 5%, PROCAM Score > 20% or Diabetes 
mellitus. Dyslipidemia treatment and control in patients with a SCORE Score > 5%, PROCAM Score > 20% or Diabetes mel-
litus (equals 100%). Displayed are the proportions of patients with known (left), treated (middle), and controlled dyslipidemia 
(right column in every age group). Reference for the first category is the total number of patients which are eligible according 
to the criteria defined; reference for subsequent percent numbers is the number of patients in the previous category.
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led (low 8.1% in the age group 41 – 50, high 18.0 to
29.7% in the elderly).
Pharmacotherapy is necessary in dyslipidemic patients
with pre-existing cardiovascular disease like myocardial
infarction, stroke, peripheral arterial disease, or heart fail-
ure. These patients are displayed in Figure 4. In these
patients, dyslipidemia was usually known (between 50
and 78% per age group), treated up to 50% of cases, and
finally controlled in up to about 20%.
Discussion
Using the ESC 2003 guidance on the treatment of dyslip-
idemia [4], which was valid at the time of this study, it was
documented that dyslipidemia was highly frequent in pri-
mary care, in particular in patients beyond the age of 40
years. Dyslipidemia in these patients was almost the rule
with prevalence rates of 85%. Many patients with a diag-
nosis of dyslipidemia were known by their primary care
physicians to be dyslipidemic, but despite life style inter-
vention and/or using pharmacotherapy dyslipidemia
were not fully controlled to the extent requested by the
recent guidelines of the ESC [4]. The chance to be diag-
nosed and subsequently controlled using pharmacother-
apy was generally higher in high risk patients and those
with known CVD. This observation is reasonable given
the recommendation to start pharmacotherapy in patients
in which cardiovascular risk exceeds the threshold of 5%
using the SCORE Score (risk of cardiovascular death
within the next 10 years) or 20% using the PROCAM
Dyslipidemia treatment and control in patients with CVD/MI/stroke/PAD and/or heart failure Figure 4
Dyslipidemia treatment and control in patients with CVD/MI/stroke/PAD and/or heart failure. Dyslipidemia 
treatment and control in dyslipidemic patients with CVD/MI/stroke/PAD and/or heart failure. Displayed is the proportion of 
patients with known (left), treated (middle) and controlled dyslipidemia (right column in every age group). Reference for the 
first category is the total number of patients which are eligible according to the criteria defined, reference for subsequent per-
cent numbers is the number of patients in the previous category.
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Score (risk of cardiovascular disease within 10 years) or in
which cardiovascular disease is already present [14].
Prevalence
In total, we documented a prevalence of dyslipidemia
using the ESC criteria of 76.4%. This figure is nominally
higher as compared to prevalence rates reported from
population-based cohort studies like MONICA [15], PRO-
CAM [16], or GRIPS [17]. Similarly studies from primary
care have reported high rates of uncontrolled dyslipi-
demia [8,9,18,19]. A meaningful comparison with results
of other studies is however difficult because of different
study populations (patient-based versus population-
based), different age-distributions, different and less tight
definitions used for dyslipidemia (i.e. TC/HDL-C ratio).
Furthermore, there are even differences between the cur-
rent guidelines in the extent of recommended LDL-C low-
ering thus giving rise to different prevalence estimates. An
example for this is a comparable recent study conducted
in primary care (DETECT) which reported prevalence
rates for dyslipidemia of approximately 50% based on the
NCEP criteria [5,7]. For example, for patients with lower
NCEP risk classifications, the European guidelines recom-
mend an optimal LDL-C level of below 115 mg/dl, while
the NCEP guidelines recommend an LDL-C below 160
mg/dl. These differences may well account for the differ-
ent prevalence rates reported.
Treatment of patients with existing CVD
A number of secondary prevention trials have shown the
benefit of lipid lowering in patients with pre-existing car-
diovascular disease [20-24]. Furthermore, because of a
high baseline risk in these patients the benefit of pharma-
cotherapy translates into a high absolute risk reduction
and in these patients statins are highly cost-effective drugs.
This is also the apparent focus in primary care in Germany
as patients with cardiovascular risk factors like type-2 dia-
betes or pre-existing cardiovascular end organ damage are
diagnosed, treated and controlled to a higher extent than
patients without. Control rates however are not sufficient
in patients in which physicians decided to use pharmaco-
therapy. Only about 55% of male and 40% of female
patients are controlled to the extent the ESC guidelines ask
for. However, this rate is substantially higher compared to
rates in hypertension, where control rates of about 20%
have been reported for primary care [25,26].
Treatment of high risk patients without existing CVD
Primary prevention is warranted only in patients not
meeting the currently accepted thresholds of the ESC or
NCEP guidelines respectively, unless their risk for cardio-
vascular death exceeds 5% or the risk of cardiovascular
events 20% including patients with diabetes [11,12,14].
This is reasonable given the risk benefit ratio of currently
available pharmacotherapy favouring the use of drugs in
high risk patients. It is also reasonable because of the price
of pharmacotherapy. Considering a substantial propor-
tion of the German population to be dyslipidemic (irre-
spective whether the ESC or the less tight NCEP guidelines
are used as a reference) it would be a substantial cost bur-
den for the health care system with an uncertain outcome.
The prices for statins have dropped over the last years, but
still the general distribution of statins to every patient
appears neither feasible nor wanted.
Perspectives
It is however unclear whether the currently available phar-
macotherapeutic options, despite being highly effective in
clinical trials, are sufficient or even suitable in clinical
practice to control dyslipidemia in a large proportion of
patients. This study clearly shows that reaching preven-
tion targets on a larger scale is very difficult to achieve.
Several steps may improve the situation: 1) Physicians
could be more aggressive to meet their patients' treatment
goals; 2) Patients should be more compliant with therapy;
3) guidelines could be tailored more to the need of physi-
cians in primary care. It may however be questioned
whether reaching these lower goals has benefit for the
individual or the collective at all. All this points to the fact
that dyslipidemia is a multifactorial disease which has to
be addressed at multiple levels to achieve long-term con-
trol. Prevention aiming at reducing the metabolic syn-
drome by increasing physical activity and controlling
waist circumference has been shown to be highly effective
if these steps are installed early enough in the course of a
person's life.
Conclusion
Treatment guidelines of the ESC are difficult to meet in
primary care. A gross proportion of patients with an indi-
cation for prevention efforts will not meet these treatment
recommendations in daily life. A call for more aggressive
treatment or higher patient compliance is apparently not
enough to enhance the proportion of well treated
patients. A shift away from a one-dimensional pharmaco-
therapy to control dyslipidemia to a multifactorial treat-
ment addressing multiple metabolic issues in these
patients considering lifestyle interventions with a reduc-
tion of body fat (BMI, WC) and an increase in physical
activity may be the only way in a population where just to
be normal might not be ideal.
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